Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of RVT-801 for Farber disease

Trial Profile

A study of RVT-801 for Farber disease

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs RVT 801 (Primary)
  • Indications Farber lipogranulomatosis
  • Focus Adverse reactions
  • Sponsors Enzyvant Sciences
  • Most Recent Events

    • 17 Oct 2017 New trial record
    • 16 Oct 2017 According to an Enzyvant Sciences media release, subject to regulatory review, the company intends to initiate this clinical trial of RVT-801 in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top